Selected Announcement of A-share | 10 dividends of 45.92 yuan. Luzhou Laojiao (000568.SZ) total dividend amount exceeds 6.7 billion yuan.

Focus today 1. Luzhou Laojiao: Cash dividend of 45.92 yuan every 10 shares in 2024, with a total dividend of about 6.759 billion yuan Luzhou Laojiao announced that the dividend payment plan for 2024 is 45.92 yuan in cash (including tax) for every 10 shares. The record date is August 7, 2025, and the ex-dividend date is August 8, 2025. The total cash dividend this time is about 6.759 billion yuan (including tax). The total share capital of the company is 1.472 billion shares, with no bonus shares, and no capital reserve fund to increase share capital. The dividend payment objects are all shareholders registered with China Securities Depository and Clearing Corporation Shenzhen Branch after the close of the Shenzhen Stock Exchange on August 7, 2025. Dividends will be distributed through China Securities Depository and Clearing Corporation Shenzhen Branch or by the company itself. 2. Tianshui Huatian Technology: Plans to set up a 2.5D/3D integrated circuit packaging and testing company with a total investment of 2 billion yuan to seize the opportunity in the advanced packaging market Tianshui Huatian Technology announced that the company plans to set up a wholly-owned subsidiary, Nanjing Huatian Advanced Packaging Co., Ltd., with a total registered capital of 2 billion yuan by its wholly-owned subsidiaries Huatian Jiangsu, Huatian Kunshan, and wholly-owned subordinate partnership enterprise Advanced One jointly. Among them, Huatian Jiangsu will contribute 1 billion yuan, accounting for 50%; Huatian Kunshan will contribute 665 million yuan, accounting for 33.25%; Advanced One will contribute 335 million yuan, accounting for 16.75%. The new company will mainly engage in 2.5D/3D integrated circuit packaging testing business, aiming to seize the opportunity in the advanced packaging market, promote the company's layout in the advanced packaging field, and enhance overall competitiveness. 3. China Petroleum Engineering: Subsidiary receives tender letter for Iraq seawater pipeline project with a value of about 18.032 billion yuan China Petroleum Engineering announced that its wholly-owned subsidiary, Pipeline Engineering Company, received a tender letter for the Iraq Basra Province Seawater Transport Pipeline EPC project with a tender amount of 2.524 billion US dollars (about 18.032 billion yuan) from Basra Oil Company in Iraq. If the project is formally signed and successfully implemented, it will benefit the company's further consolidation and expansion in the oil and gas storage and transportation engineering market in Iraq and even the Middle East region, and will have a positive impact on the company's operating income and total profit for the next 4-5 years. However, the project is currently in the stage of winning the bid and waiting to sign the contract, and there is uncertainty as to whether a formal contract can be signed. 4. Nexchip Semiconductor Corporation: Planning to issue H shares and list on the Hong Kong Stock Exchange Nexchip Semiconductor Corporation announced that it is planning to issue overseas listed shares (H shares) and list on the Hong Kong Stock Exchange. The company is in discussions with relevant intermediaries on the specific progress of this H-share listing, and the details have not been finalized yet. This H-share listing will not cause changes to the company's controlling shareholders and actual controllers. 5. Shandong Wit Dyne Health: Subsidiary signs exclusive distributor contract for melatonin granules (Manlejing) Shandong Wit Dyne Health announced that its subsidiary, Beijing Dain Health, has reached an agreement with Japan's Nobren Pharmaceutical Co., Ltd. on the exclusive distribution of melatonin granules (Manlejing) in mainland China, and signed the "Melatonin Granules Exclusive Distribution Agreement." Dain Health will become the exclusive distributor for the product in mainland China (excluding Hong Kong, Macau, and Taiwan). The product was approved for listing in China in July 2025 under the name "Manlejing." This product is the first melatonin preparation approved in China for the treatment of sleep difficulties in children aged 6-15 with neurodevelopmental disorders, and is also the first time that a melatonin substance has obtained marketing approval in China in the form of a drug. 6. Bio-Thera Solutions: Innovative drug recombinant anti-VEGF humanized monoclonal antibody injection (BAT5906) receives clinical trial approval Bio-Thera Solutions announced that it has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the investigational drug recombinant anti-VEGF humanized monoclonal antibody injection (BAT5906) for the indications of central retinal vein occlusion-related macular edema (CRVO-ME) and pathologic myopia choroidal neovascularization (pmCNV). BAT5906 is an innovative recombinant humanized monoclonal antibody drug independently developed and produced by Bio-Thera Solutions. Currently, the company has completed Phase I, II, and III clinical studies for BAT5906 in the w-AMD indication, Phase II clinical studies for the DME indication, and is in the preparatory stage for Phase II/III clinical studies for the CRVO-ME and pmCNV indications. Business Performance 1. Verisilicon Microelectronics (Shanghai) Co., Ltd.: Expected operating income of about 584 million yuan in the second quarter, a 49.9% increase from the previous quarter 2. Chongqing Qianli Technology: Car sales in July were 10,200 units, a year-on-year increase of 142.34 3. Hanma Technology Group: Truck sales in July were 956 units, a year-on-year increase of 42.69% 4. Beijing Tianyishangjia High-tech Material Corp., Ltd.: Expected net loss attributable to shareholders of 190 million to 240 million yuan in the first half of the year Stock Movement Risk Warning 2 consecutive boards for Perfect Group Corp., Ltd: From July 23 to July 28, Xiaobei No. 1 and No. 2 reduced their holdings by 1.025 million shares and 575,000 shares respectively. Major Deals 1. ABA Chemicals Corporation: Signed a strategic supply agreement with Jiangsu Hengrui Pharmaceuticals 2. Willfar Information Technology: Won a total of 110 million yuan procurement projects from Southern Grid and State Grid 3. OMH SCIENCE Group: Received a procurement order from PTT LOGISTICS SDN BHD with a value of about 62.5 million yuan Repurchase & Increase/Decrease Holdings 1. GuangZhou BaiYun Electric Equipment: Plans to repurchase shares with 10 million to 20 million yuan 2. Sinotrans Limited: Plans to increase its holdings in Antong Holdings by 300 million to 600 million yuan 3. Yusys Technologies: Controlling shareholder plans to reduce holdings of up to 1.50% of the company's shares 4. Beijing Forever Technology: Shareholder with more than 5% stake, Chen Xianlong, plans to reduce holdings of up to 1.50% of the company's shares 5. Sichuan Zhongguang Lightning Protection Technologies: Chairman and general manager Wang Xueying and other executives plan to reduce their holdings Others Ningbo Cixing: Termination of restructuring matters This article is reproduced from "Tencent's own stock selection", GMTEight editor: Jiang Yuanhua.